Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Avelumab Plus Cisplatin-Based Chemotherapy Yields High EFS and OS Rates in MIUC

June 4th 2024

The addition of avelumab to cisplatin-based chemotherapy led to high event-free survival and overall survival rates in patients with muscle-invasive urothelial carcinoma.

KIM-1 Shows Prognostic and Predictive Value With Adjuvant Atezolizumab in RCC

June 3rd 2024

Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease (MRD), disease recurrence, and benefit from adjuvant atezolizumab (Tecentriq) in patients with renal cell carcinoma (RCC) at increased risk of recurrence.

PRO Data Add to Efficacy and Safety of Frontline Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Carcinoma

June 3rd 2024

Enfortumab vedotin plus pembrolizumab did not negatively affect quality of life in patients with advanced urothelial carcinoma.

mIF Biomarker Not Associated With Improved Outcomes With Nivolumab/Ipilimumab Treatment in Metastatic Clear Cell RCC

June 2nd 2024

Using CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative TILs as a biomarker was not associated with improved clinical outcomes for patients with mccRCC treated with nivolumab plus ipilimumab.

Neoadjuvant Sacituzumab Govitecan Displays Activity in Muscle-Invasive Bladder Cancer, But Questions Remain

June 1st 2024

Neoadjuvant sacituzumab govitecan demonstrated efficacy in patients with muscle-invasive bladder cancer, but its future role in the space is uncertain.

Dr Narayan on the Utility of Nadofaragene Firadenovec in NMIBC and Beyond

May 29th 2024

Vikram M. Narayan, MD, discusses the utility of nadofaragene firadenovec in patients with non–muscle-invasive bladder cancer and beyond.

Frontline Nivolumab/Chemo Approved in Europe for Unresectable or Metastatic Urothelial Cancer

May 29th 2024

The European Commission approved nivolumab plus cisplatin and gemcitabine for first-line treatment in unresectable or metastatic urothelial carcinoma.

Narayan Discusses Bladder Preservation and the Role of Gene Therapies in NMIBC

May 23rd 2024

Vikram M. Narayan, MD, highlights takeaways from 5-year follow-up data examining the gene therapy nadofaragene firadenovec and details promising emerging therapies for bladder cancer.

Advances With Erdafitinib Exemplify the Push For Precision Medicine in Urothelial Cancer

May 23rd 2024

Petros Grivas, MD, PhD, expands on key updates in the second-line management of urothelial cancer.

Expansion of Frontline Immunotherapy Regimens Improves Prognosis, Increases Optimism in Urothelial Cancer

May 22nd 2024

Peter H. O’Donnell, MD, provides insights on key developments in bladder cancer management and how they have generated optimism within the field.

Dr Narayan on Long-Term Results With Nadofaragene Firadenovec in NMIBC

May 17th 2024

Vikram M. Narayan, MD, discusses the final 5-year analysis of a phase 3 trial of nadofaragene firadenovec in patients with BCG-unresponsive NMIBC.

Dr Gopal on a Case Study of a Patient With Bladder Cancer

May 16th 2024

Nikhil Gopal, MD, discusses details from a case discussion of a patient with bladder cancer.

Dr Rosenberg on Efforts to Enhance Urothelial Cancer Treatment

May 15th 2024

Jonathan E. Rosenberg, MD, discusses ongoing and planned research efforts to enhance the frontline and beyond urothelial cancer treatment landscape.

Nadofaragene Firadenovec Sets the Stage for Gene Therapies in NMIBC

May 15th 2024

As investigators parse out the mechanism of action of nadofaragene firadenovec, additional gene therapies are under development in BCG-unresponsive NMIBC.

Grivas Spotlights Advances With Immunotherapy-Based Approaches in Urothelial Cancer

May 14th 2024

Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.

Dr Bellmunt on Enfortumab Vedotin/Pembrolizumab in the Community Setting for Urothelial Carcinoma

May 13th 2024

Joaquim Bellmunt, MD, PhD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.

EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer

May 10th 2024

Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

May 6th 2024

No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.

Dr Siefker-Radtke on the Safety of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

May 6th 2024

Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.

TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer

May 5th 2024

TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.